Firering Strategic Minerals: From explorer to producer. Watch the video here.
Jimmy, on my computer I have a couple of Post it Notes:
Why didn't I tell them? Well I tried and most didn't listen!
One day you will thank yourself for not giving up!
We all have the same hard working 24h. Don't beat yourself up. Most people would not listen, let alone take action and certainly not invest to the level that many of us have even if you did tell them. It will only be life changing for those that have really heard what AS and his team have had to say and for those that are on the receiving end of Avacta's transformational science.
Just for you RAH!
At the AGM, AS also said, "We will be trying to determine whether there is a MTD, we don't know yet whether a MTD will be received but I guess it begs the question, what if we go for a fourth cohort and there isn't a MTD? That is down to the clinicians to decide whether that is the point you stop and you recommend a phase 2 or phase 1b dose. You don't have to reach a MTD in one of these studies in order to progress."
Someone else in the room said, "I take that as a positive decision, because obviously you have seen the data and it's fairly positive.
AS went on to say: "The statement is just factual, If one is reached. I am not going to get drawn on the data at the moment, it's not appropriate but the fact is, we may not reach a MTD. He pauses and then says, "Well, that would be good wouldn't it!" Everyone agrees and laughs.
At the AGM, AS also said, "We will be trying to determine whether there is a MTD, we don't know yet whether a MTD will be received but I guess it begs the question, what if we go for a fourth cohort and there isn't a MTD? That is down to the clinicians to decide whether that is the point you stop and you recommend a phase 2 or phase 1b dose. You don't have to reach a MTD in one of these studies in order to progress."
Someone else in the room said, "I take that as a positive decision, because obviously you have seen the data and it's fairly positive.
AS went on to say: "The statement is just factual, If one is reached. I am not going to get drawn on the data at the moment, it's not appropriate but the fact is, we may not reach a MTD. He pauses and then says, "Well, that would be good wouldn't it!" Everyone agrees and laughs.
A possible way forward and a new thread for 'does it work?'
Perhaps in the future there will be no need for surgery if you have cancer.
Perhaps in the future, one of the PreCISION prodrugs will be administered and the tumours will be destroyed. Perhaps in the future, they will use TMac and not only will the tumour be destroyed but the patient will then have immunity so the cancer can not come back!
This is Avacta's ambition if you listen to what AS really has to say.
Extravasation is the leakage of an injected drug out of the blood vessels, damaging the surrounding tissues. In terms of cancer therapy, extravasation refers to the inadvertent infiltration of chemotherapeutic drugs in the tissues surrounding the IV site.
RAH wrote earlier today:
Further more, one which is very exciting for patients: there are lots of reports (50 years worth) of dox ‘burn’
I.e. “ a risk that this medication may leak out of the vein at the injection site, resulting in tissue damage that can
be severe”
If AVA6000 is ‘inert’ on injection you have a BBC news headline right there…
Note graphic images: https://www.google.com/search?q=doxorubicin+extravasation&tbm=isch&ved=2ahUKEwjH0aHun9r4AhUJ-xoKHbH3BX8Q2-cCegQIABAA&oq=doxorubicin+extrav&gs_lcp=CgNpbWcQARgBMgUIABCABDIFCAAQgAQyBQgAEIAEMgYIABAeEAgyBAgAEBgyBAgAEBgyBAgAEBgyBAgAEBhQrgxYqxhgiyRoAHAAeACAAUeIAbEDkgEBN5gBAKABAaoBC2d3cy13aXotaW1nwAEB&sclient=img&ei=0T_AYoelFon2a7Hvl_gH&bih=860&biw=1891
Treatment of a vesicant extravasation includes immediate cessation of infusion, aspiration of as much extravasated drug as possible through the still-intact catheter, and attempts for the aspiration of the extravasated agent in the surrounding tissue. This aspiration may help to limit the extent of tissue necrosis or formation of blisters/burns.
At the AGM Alastair Smith suggested that there should be at least two LG Chem payments this year. The IND filing should not take very long so perhaps another one for when clinical trials actually start.
They did a pre AGM and business update last year via Investor Meet as their was guidance not to attend the AGM
https://www.investormeetcompany.com/investor/meeting/business-update-and-qa
Oldtrader2 - hope this helps
The Annual General Meeting will be held on Thursday, 23 June 2022 at 3.30 p.m. BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD. Shareholders who plan to attend are required to register their attendance and prove their shareholding by email to investors@avacta.com.
Thanks SeethreeIPO, I was looking at the patientwing info earlier. Not sure if the trial was going to stick with just three tumour types for 1b having worked with all tumours on the list for 1a. As you say, better to offer the info and let her ask.
"The dose expansion phase will comprise of 1 to 3 expansion arms in specific tumour types. "
Can anyone tell me what the three specific tumour types are that will be targeted for phase 1b dose expansion?
Sadly we have a friend will bowel cancer and she has just been given 18m to live. I want to talk to her about the AVA6000 trial - was bowel one of the three arms or it is yet to be decided?
Click on Q&A link
https://www.investormeetcompany.com/investor/meeting/final-results-21